Home › NCT06523868

Evaluation of Multi-Cancer Early Detection Testing in a High-Risk Military Population: The Sentinel Study

Who can join

Ages 45 and older · All sexes · Healthy volunteers welcome

Inclusion Criteria:

* Active-duty or National Guard/Reserves military service for four or more years
* Age ≥ 45
* Received care at a VA facility within past 5 years
* Able to sign informed consent
* Willingness to travel to Dana-Farber Cancer Institute in Boston, MA, for diagnostic testing if screening test indicates possible malignancy

Exclusion Criteria:

* Individuals diagnosed with invasive malignancy within 3 years of enrollment (non- melanoma skin cancer is acceptable)
* Individuals with evidence of symptomatic or active cancer requiring therapeutic intervention at the time of participation (hormone therapy for breast/prostate cancer is acceptable)
* Individuals in the process of being evaluated for a clinical suspicion of cancer

About the study

The purpose of this research study is to evaluate the possible benefits of an investigational, but commercially available Galleri multi-cancer early detection (MCED) blood test which is designed to detect many types of cancer early in veterans who have served in the military in active duty.

The name of the screening blood test being studied is:

-GRAIL Galleri MCED test

What is being tested

• GRAIL Galleri (other)

Sponsor: Dana-Farber Cancer Institute · Participants: 1,500 · Started: Mar 31, 2025

Contact the study team

• Elizabeth ODonnell, MD · Phone: 857-215-2361

Official record on ClinicalTrials.gov — NCT06523868

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.